Have a question or topic idea for The Life Science Report? Submit it here.
Life Science SPACs
Ahead of our financing forum on June 17th with Endpoints News, Back Bay's investment banking leads discuss the current landscape of life science SPACS. The feeling surrounding healthcare SPACs right now is almost giddy. With enormous capital flowing into the biotech sector, SPACs have emerged as one of the hottest financing options. Last year, the market saw $80B in SPAC issuance, which 2021 will far exceed. We are still at the beginning of this market shift, but is the SPAC vehicle the right vehicle to fund the strategy of science? Topics include:
Traditional IPO markets vs. the hot market of SPACs
How COVID affected the SPAC landscape
The delicate balance of near-term data, valuations & due diligence
Cautions, concerns & the importance of the use of proceeds
Regulators & litigation risks in biotech
The potential of U.S. SPAC markets for European companies.
Subscribe to Back Bay's Life Science Report podcast on any major podcast player. Please join the conversation: send us your comments and questions.
Subscribe:
Apple Podcasts | Libsyn | Spotify | Stitcher
